Loading
Life sciences · Journal article
Bioconjugate Chemistry · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Antibody drug conjugates (ADCs) are a key therapy in the cancer treatment arsenal. Critical to the success of the ADC is the release of the drug cargo at the desired site, and thus, enzymatically or chemically responsive linkers, connecting the drug to the antibody, play a central role. Linkers containing the peptide sequence Glu-Val-Cit are particularly important as cleavage of this peptide occurs by both murine and human cathepsin B enzymes. Additional linker design considerations include components for free drug release via the self-immolative moiety para-aminobenzyl alcohol (PABOH), copper-free click conjugation to an azide-functionalized antibody using dibenzocyclooctyne (DBCO), and aqueous solubility via a polyethylene glycol spacer (PEG). To facilitate widespread use and translation, we describe the 9-step gram-scale synthesis of the linker DBCO-PEG4-Glu-Val-Cit-PABOH conjugated to monomethyl auristatin E (MMAE). Using only liquid-phase synthesis protocols and chromatography-free, precipitation-based intermediate isolations gives the drug-linker conjugate in 36% overall yield, and this method is an improvement over prior methods (yield < 1%). Finally, we prepare the corresponding MMAE-linked ADC and validate its target-dependent potency across ErbB2/Her2-high (MDA-MB-453) and ErbB2/Her2-low (MDA-MB-231) human breast cancer cell lines.